Delivery Order SPE2DB22D2206-SPE2DB25FJE09
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,262.40 to AmerisourceBergen Drug Corp for the supply of Cathflo Activase 2 mg vials, a thrombolytic medication used to restore function to central venous catheters. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and was competitively awarded without set-aside restrictions. AmerisourceBergen's Corporate Office division, headquartered in Conshohocken, Pennsylvania,...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $12,558.77 by the Defense Logistics Agency on July 21, 2025, for the supply of Cathflo Activase 2 mg vials. This contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The ultimate completion date is scheduled for July 22, 2025, with performance occurring at the contractor's Conshohocken...
- The Defense Logistics Agency awarded a delivery order valued at $12,949.43 to AmerisourceBergen Drug Corp for the supply of Cathflo Activase 2 mg vials under a firm fixed-price contract. This non-set-aside award, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a routine pharmaceutical procurement from the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order is executed under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,374.60 for Cathflo Activase 2 mg vials, effective July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed price delivery order was awarded without a set-aside designation through open competition and will be performed at the contractor's Conshohocken, Pennsylvania facility. Cathflo Activase is a thrombolytic agent used in medical settings to restore function to occluded...
- This delivery order, valued at $4,524.80, was awarded to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Cathflo Activase 2 mg vials. The contract is a firm fixed price, non-set-aside award funded by the Defense Logistics Agency (DLA) and is scheduled for completion by July 21, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a discrete purchase under the company's broader pharmaceutical...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,090.40, is for the delivery of 2 mg vials of Cathflo Activase, a medication used to treat certain blood clots. The contract has an ultimate completion date of April 11, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The contract, valued at $8,126.50, is for the provision of 2 mg vials of the medication Cathflo Activase. This delivery order does not have a set-aside designation. Amerisourcebergen Drug Corp, through its Corporate Office division in Conshohocken, Pennsylvania, is the prime...
- This is a federal contract award issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $28,484.84 and an ultimate completion date of May 23, 2025. The contract provides for the delivery of CATHFLO ACTIVASE 2 MG VIALS, a pharmaceutical product, to be performed at a location in Conshohocken, Pennsylvania. This contract is not set-aside and...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The $1,070.90 order is for 2 milligram vials of Cathflo Activase, a pharmaceutical product. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 2025. This IDC serves as the primary vehicle for Amerisourcebergen to...
- The Defense Logistics Agency awarded a delivery order valued at $22,365.75 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. This firm fixed price contract, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The award was made through competitive procurement with no set-aside designation. Performance will take place at...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJE09Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $16,297.10 to AmerisourceBergen Drug Corp for the supply of Cathflo Activase 2 mg vials, a thrombolytic medication used in medical applications. The contract was executed as a firm fixed-price delivery order on July 31, 2025, with an ultimate completion date of August 1, 2025, and does not include a set-aside designation. Performance will be fulfilled at the vendor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through its DLA prime indefinite delivery contract valued at $999,999,999.00 and extending through December 2026. This comprehensive vehicle enables the company to supply pharmaceutical products and medical supplies to military healthcare systems worldwide. The Cathflo Activase delivery order reflects the company's ongoing role in supporting military medical logistics across multiple therapeutic domains, fulfilling DLA's pharmaceutical supply requirements through competitively awarded contracts with firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.3k | 7/31/25 |